Dimensional Fund Advisors LP Has $12.54 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Key Points

• Dimensional Fund Advisors increased its Amylyx Pharmaceuticals stake by 17.1% in the first quarter, owning 903,192 shares valued at approximately $12.54 million. Institutional investors collectively hold 95.84% of AMLX shares.
• Amylyx shares opened at $22.82, near their 12-month high of $24.60, but were reported as trading down 5.7%. The company posted quarterly EPS of -$0.39, missing analysts’ estimate of -$0.36.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $25.38, although one analyst issued a sell rating. Insider Gina Mazzariello also sold 15,000 shares for $274,800.

Dimensional Fund Advisors LP boosted its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 17.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 903,192 shares of the company's stock after purchasing an additional 131,944 shares during the period. Dimensional Fund Advisors LP owned about 0.81% of Amylyx Pharmaceuticals worth $12,544,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. lifted its stake in shares of Amylyx Pharmaceuticals by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company's stock valued at $56,408,000 after acquiring an additional 3,102,395 shares during the last quarter. Perceptive Advisors LLC grew its position in Amylyx Pharmaceuticals by 0.4% during the 2nd quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company's stock worth $50,654,000 after acquiring an additional 28,017 shares during the last quarter. TCG Crossover Management LLC increased its holdings in Amylyx Pharmaceuticals by 5.0% in the 3rd quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company's stock worth $84,853,000 after purchasing an additional 300,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in Amylyx Pharmaceuticals by 10.1% in the 4th quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company's stock worth $70,123,000 after purchasing an additional 531,162 shares in the last quarter. Finally, Commodore Capital LP raised its position in Amylyx Pharmaceuticals by 38.6% in the fourth quarter. Commodore Capital LP now owns 5,650,000 shares of the company's stock valued at $68,252,000 after purchasing an additional 1,574,522 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.

Amylyx Pharmaceuticals Trading Down 5.7%

NASDAQ AMLX opened at $22.82 on Friday. The business's 50-day moving average price is $17.36 and its two-hundred day moving average price is $15.76. Amylyx Pharmaceuticals, Inc. has a 12 month low of $7.48 and a 12 month high of $24.60. The firm has a market capitalization of $2.54 billion, a PE ratio of -15.96 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). As a group, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMLX. Wall Street Zen lowered Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Mizuho upped their price objective on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an "outperform" rating in a research note on Monday, July 20th. Citigroup raised their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a report on Monday, August 3rd. HC Wainwright reiterated a "buy" rating and set a $34.00 target price on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. Finally, Guggenheim lifted their target price on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $25.38.

Insider Activity

In other news, insider Gina Mazzariello sold 15,000 shares of the company's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the sale, the insider directly owned 194,090 shares of the company's stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 10.90% of the company's stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source